Ionis Pharmaceuticals, Inc. Equity Securities, FV-NI, Unrealized Loss
Ionis Pharmaceuticals, Inc. (IONS) reported Equity Securities, FV-NI, Unrealized Loss of $606.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2019-11-06
- Ionis Pharmaceuticals, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2019-09-30 was $290.00K.
- Ionis Pharmaceuticals, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2019-06-30 was $72.00K.
- Ionis Pharmaceuticals, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2019-03-31 was $244.00K.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2019-09-30 | $290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $362.00K derived: sum of 2 quarters · filed 2019-11-06 | $606.00K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $316.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $244.00K 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $0.00 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |